Lynne Ward Sells 5,000 Shares of Merit Medical Systems (NASDAQ:MMSI) Stock

Merit Medical Systems, Inc. (NASDAQ:MMSI) Director Lynne Ward sold 5,000 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the completion of the transaction, the director owned 7,809 shares in the company, valued at $488,921.49. This represents a 39.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Merit Medical Systems Stock Up 1.4%

NASDAQ:MMSI opened at $61.15 on Wednesday. Merit Medical Systems, Inc. has a 12-month low of $59.74 and a 12-month high of $100.05. The company has a quick ratio of 3.46, a current ratio of 5.08 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $3.65 billion, a P/E ratio of 26.47, a P/E/G ratio of 1.88 and a beta of 0.58. The stock’s fifty day simple moving average is $68.41 and its 200-day simple moving average is $78.88.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.10. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The business had revenue of $381.88 million for the quarter, compared to analyst estimates of $377.59 million. During the same period last year, the company earned $0.86 EPS. The firm’s revenue was up 7.4% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Equities research analysts expect that Merit Medical Systems, Inc. will post 3.61 earnings per share for the current year.

Institutional Trading of Merit Medical Systems

Hedge funds and other institutional investors have recently modified their holdings of the company. Los Angeles Capital Management LLC acquired a new stake in shares of Merit Medical Systems in the 4th quarter valued at about $25,000. Maseco LLP acquired a new stake in shares of Merit Medical Systems in the 4th quarter valued at about $26,000. Torren Management LLC acquired a new stake in shares of Merit Medical Systems in the 4th quarter valued at about $38,000. Covestor Ltd raised its stake in shares of Merit Medical Systems by 252.6% in the 4th quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 336 shares during the period. Finally, Danske Bank A S acquired a new stake in shares of Merit Medical Systems in the 3rd quarter valued at about $42,000. Institutional investors and hedge funds own 99.66% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on MMSI. Wall Street Zen lowered Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 5th. Compass Point set a $107.00 target price on Merit Medical Systems in a report on Monday, April 20th. Canaccord Genuity Group reduced their target price on Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Piper Sandler reduced their target price on Merit Medical Systems from $106.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Finally, Citigroup reiterated an “outperform” rating on shares of Merit Medical Systems in a report on Monday, April 20th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $92.80.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.